First Drug Approved for Rare Lung Disease

Nintedanib (Ofev) is the first drug approved for the treatment of SSc-ILD, a rare interstitial lung disease associated with systemic sclerosis or scleroderma. This is a new indication for nintedanib, which was previously approved for idiopathic pulmonary fibrosis.
Source: AJN - Category: Nursing Tags: Drug Watch Source Type: research